A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants
Launched by ELI LILLY AND COMPANY · Sep 15, 2023
Trial Information
Current as of May 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male participants who are overtly healthy as determined by medical evaluation
- • Have a body mass index of 18.5 to 32.0 kilograms per meter squared (kg/m²), inclusive
- • Males who agree to use highly effective or effective methods of contraception
- Exclusion Criteria:
- • Have known allergies to LY3871801, related compounds, or any components of the formulation, or a history of significant atopy
- • Have received or intend to receive any vaccination within 30 days prior to dosing until the follow-up phone call
- • Have participated in a radiolabeled drug study, where exposures are known to the investigator or designee, within 4 months prior to check-in, or participated in a radiolabeled drug study, where exposures are not known to the investigator or designee, within 6 months prior to check-in
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madison, Wisconsin, United States
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported